The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 11, 1983
Filed:
Nov. 10, 1982
Applicant:
Inventors:
Eric W Collington, Welwyn, GB;
Harry Finch, Hitchin, GB;
Roger F Newton, Melbourn, GB;
Christopher J Wallis, Royston, GB;
Assignee:
Glaxo Group Limited, , GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K / ; A61K / ; C07D / ; C07D / ;
U.S. Cl.
CPC ...
424244 ; 544396 ; 544399 ; 424 45 ; 544400 ; 546187 ; 424246 ; 546188 ; 546190 ; 4242485 ; 546208 ; 546216 ; 42424853 ; 546217 ; 546230 ; 42424855 ; 546232 ; 546233 ; 424250 ; 546234 ; 546235 ; 424267 ; 546238 ; 546239 ; 424274 ; 542426 ; 560 10 ; 424304 ; 560 16 ; 560 36 ; 424309 ; 560 43 ; 560121 ; 424305 ; 562426 ; 562441 ; 424319 ; 562444 ; 562448 ; 544 581 ; 562452 ; 562455 ; 544 582 ; 562456 ; 562457 ; 544 585 ; 562433 ; 562503 ; 544 586 ; 2602433 ; 2602444 ; 544 587 ; 2602457 ; 2602 / ; 544 82 ; 2603306 ; 2604 / ; 544 85 ; 548523 ; 548566 ; 544 86 ; 548567 ; 548573 ; 544 87 ; 544121 ; 544130 ; 544141 ; 544160 ; 544163 ; 544165 ; 544169 ; 544171 ; 544357 ; 544360 ; 544372 ;
Abstract
Prostanoid compounds are described having the formula: ##STR1## where A is a cyclopentane ring, which is substituted by oxo and/or hydroxy or etherified hydroxy and may be saturated or unsaturated; X is --CH.dbd.CH-- or --(CH.sub.2).sub.2 --; R is alkyl having a terminal --COOH or ester group; and Y is amino or substituted amino, particularly heterocyclic amino. The compounds have bronchodilator activity and/or inhibit blood platelet aggregation. The preparation and pharmaceutical formulation of the compounds is also described.